Enterobacteriaceae Infections
Conditions
Keywords
Antibiotic resistance, ESBL carriage
Brief summary
Multidrug-resistant Enterobacteriaceae producing extended-spectrum β-lactamases (hereafter called ESBLs) have emerged as an important cause of bloodstream infection in hospitalized patients and urinary tract infections in the community. As is the case with other multidrug-resistant organisms chronic colonization is frequent, in the case of ESBLs mostly intestinal and urinary carriage. To the investigators knowledge no randomized, placebo-controlled clinical trial has been performed to study the efficacy of a systematic ESBL eradication strategy. Eradication of ESBL carriage would cause benefits for the individual patient - by reducing the risk of infection - and for the community - by reducing transmission. Even if eradication turns out to be impossible, transient suppression of ESBL might reduce the likelihood of transmission and thus still be beneficial from an ecologic perspective. The purpose of the proposed study is to test the hypothesis that the administration of a 10 day course of oral antibiotics active against ESBLs can lead to decolonization of ESBL carriage in hospitalized patients.
Interventions
DRUGDecolonization
Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days
DRUGPlacebo (Decolonization)
Placebo
Sponsors
University Hospital, Geneva
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients can be enrolled into the study provided that all of the following criteria are met: 1. Microbiologically documented rectal carriage of ESBL-producing Enterobacteriaceae, without signs and symptoms of active infection with ESBL-producing Enterobacteriaceae at any body site 2. Patient must give written informed consent to participate in the study. The informed consent can be given by the legal representative if necessary.
Exclusion criteria
1. Women who are pregnant or nursing 2. Active infection 3. Treatment with antimicrobial agents with activity against ESBL-producing Enterobacteriaceae 4. Contraindication to the use of one of the study drugs (e.g. renal insufficiency with creatinine clearance \< 30 ml/min) 5. Patient already enrolled in another study, or in the present study for a previous episode 6. Psychiatric disorder or unable to understand or to follow the protocol directions 7. Permanent indwelling urinary catheter that can not be changed 8. Resistance of the ESBL-producing Enterobacteriaceae to one of the study drugs 9. Known hypersensitivity to one of the study drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of eradication of carriage with ESBL-producing Enterobacteriaceae at day 28 post-treatment | 28 days |
Countries
Switzerland
Outcome results
None listed